• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

U.S. Looks Bad in International COVID-19 Comparisons

Publication
Article
MHE PublicationMHE November 2020
Volume 30
Issue 11

The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.

The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.

The story with COVID-19 is similar, according to data reported recently by Kaiser Family Foundation. Among the dozen developed countries included in the foundation’s analysis, only Belgium, at 90.4 COVID-19-related deaths per 100,000 population, was worse than the U.S., at 66.5 COVID-19 deaths per 100,000. By contrast, Japan’s rate of 1.3 COVID-19 deaths per 100,000 is stunningly low, as is Australia’s (3.6 per 100,000) and Germany’s (11.7 per 100,000).

Kaiser’s ranking of the leading causes of death is also sobering. COVID-19 is on course to being the third leading cause of death in the U.S. in 2020, behind only the perennial leaders, heart disease and cancer. In Japan, COVID-19 is on track to being the 29th leading cause of death and in Germany, the 17th

Related Videos
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Video 8 - "Demographic Differences That Impact Care"
Related Content
© 2024 MJH Life Sciences

All rights reserved.